Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Regimen shows promise as salvage for classical HL
Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.
Major finding: Of 28 patients, 27 responded to BV-IGEV.
Study details: A retrospective study of 28 patients.
Disclosures: The authors reported having no conflicts of interest.
Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.
This Week's Must Reads
Must Reads in Hodgkin Lymphoma
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.